Highlights
- •Angiogenesis inhibition is a valuable strategy for epithelial ovarian cancer (EOC).
- •Gemcitabine plus pazopanib improves PFS in patients with platinum resistant EOC over gemcitabine alone.
- •Overall response rate is higher in the gemcitabine plus pazopanib arm.
Abstract
Objective
Angiogenesis inhibition is a valuable strategy for ovarian cancer (EOC). Pazopanib
(paz) is a potent small molecular inhibitor of VEGF-1, -2, -3, PDGFR, c-kit, and has
activity as a single agent in ovarian cancer. We designed a trial to assess the benefit
of adding paz to gemcitabine (gem) in patients with recurrent EOC.
Methods
An open-label, randomized, multi-site, phase 2 trial was conducted (NCT01610206) including
patients with platinum resistant or sensitive disease, ≤ 3 prior lines of chemotherapy,
and measurable/evaluable disease. Patients were randomly assigned to weekly gem 1000 mg/m2 on days 1 and 8 of a 21 day cycle, with or without paz 800 mg QD, stratified by platinum
sensitivity and number of prior lines (1 vs 2 or 3). The primary endpoint was PFS.
Results
148 patients were enrolled 2012–2017. Median age was 63 years (30–82); 60% were platinum
resistant; median surveillance was 13 months (0.4–54 months). Median PFS was 5.3 (95%
CI, 4.2–5.8) vs 2.9 months (95% CI, 2.1–4.1) in the gem arm. The PFS effect was most pronounced in
the platinum resistant group (5.32 vs 2.33 months Tarone-Ware p < 0.001). There was no difference in OS. Overall RR (PR
20% vs 11%, Chi-squre p = 0.02) and DCR (80% vs 60%, Chi-square p < 0.001) were higher in the combination. High grade AEs in the
combination arm included ≥ Grade 3: hypertension (15%), neutropenia (35%), and thrombocytopenia
(12%).
Conclusions
The addition of paz to gem enhanced anti-tumor activity; those with platinum-resistant
disease derived the most benefit from combination therapy, even in the setting of
receiving prior bevacizumab.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Gynecologic OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer statistics.CA Canc. J. Clin. 2018; 68 (2018): 7-30
- Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.Br. J. Canc. 2012; 107: 588-591
- Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.Gynecol. Oncol. 2015; 139: 10-16
- Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial.J. Clin. Oncol. 2014; 32: 1302-1308
- Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.Gynecol. Oncol. 2003; 88: 266-269
- Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.J. Clin. Oncol. 2008; 26: 890-896
- Gemcitabine as a single-agent treatment for ovarian cancer.Gynecol. Oncol. 2003; 90: S21-S23
- Gemcitabine: current role and future options in the treatment of ovarian cancer.Crit. Rev. Oncol. Hematol. 2003; 48: 81-88
- Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.Gynecol. Oncol. 2003; 90: 593-596
- Gemcitabine in patients with ovarian cancer.Cancer Treat Rev. 2005; 31: S29-S37
- Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients.Acta Oncol. 2006; 45: 463-468
- Role of gemcitabine in ovarian cancer treatment.Ann. Oncol. 2006; 17: v188-v194
- Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives.Int. J. Gynecol. Cancer. 2005; 15: 1002-1013
- A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.Ann. Oncol. 1998; 9: 1343-1345
- OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.J. Clin. Oncol. 2012; 30: 2039-2045
- Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis.Cancer Chemother. Pharmacol. 2018; 81: 809-814
- Feasibility of bevacizumab combined with gemictabine in treatment of platinum-resistant epithelial ovarian cancer.J. Clin. Oncol. 2017; 35
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.Gynecol. Oncol. 2010; 119: 32-37
- Incorporation of pazopanib in maintenance therapy of ovarian cancer.J. Clin. Oncol. 2014; 32: 3374-3382
- Ago-ovar 16: a phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—overall survival (OS) results.J. Clin. Oncol. 2018; 36 (May 20 2018): 5518
- Sample sizes based on the log-rank statistic in complex clinical trials.Biometrics. 1988; 44: 229-241
- Designing complex group sequential survival trials.Stat. Med. 2002; 21: 1969-1989
- Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer: a randomized clinical trial.JAMA Oncol. 2018; 4: 196-202
- Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.Lancet Oncol. 2015; 16: 561-568
Article info
Publication history
Published online: April 01, 2020
Accepted:
October 13,
2019
Received in revised form:
October 6,
2019
Received:
July 26,
2019
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
